Pfizer Inc. (PFE) Earnings Analysis

Pfizer Inc. (PFE) delivered mixed results in FY2026 on revenue of $113.4B versus the $111.6B estimate (+14.7% YoY) and EPS of $3.40. Below is the full Pfizer Inc. earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.

Pfizer Inc. (PFE) Earnings Analysis — key stats

Latest reported quarterFY2026
Earnings verdictMixed
Revenue$113.4B (vs $111.6B est · +1.6% surprise · +14.7% YoY)
EPS$3.40 (vs $3.31 est · +2.7% surprise · -14.2% YoY)
Share price$555.78 (+2.6%)
Market cap$1.11T

What you'll find

Frequently asked questions

When is Pfizer Inc.'s next earnings date?
Magnisto tracks Pfizer Inc.'s (PFE) earnings schedule and shows the confirmed next earnings date, the options-implied expected move and the estimates analysts are modeling into the print.
Did Pfizer Inc. (PFE) beat or miss earnings?
In FY2026, Pfizer Inc. (PFE) posted mixed results — revenue of $113.4B versus the $111.6B estimate (+1.6% surprise) and EPS of $3.40 versus $3.31 expected (+2.7% surprise). Magnisto decodes every Pfizer Inc. (PFE) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
What is the forecast for Pfizer Inc. (PFE) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Pfizer Inc. (PFE), anchored to the current $555.78 share price, so you can weigh the bull, base and bear cases for Pfizer Inc. side by side.
Is Pfizer Inc. (PFE) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Pfizer Inc. fits your own thesis and risk profile. This is research, not investment advice.

Related stocks

Educational research, not investment advice. Figures are illustrative and may be delayed.